Original Research Articles from Managed Care
Sulfonylureas are cost-effective and also may be the only oral agents that inhibit processes inducing hyperglycemia by improving insulin secretion and insulin resistance. New long-acting agents hold even greater promise.
In response to the expense of new migraine therapies, treatment practices aimed at controlling direct costs are now the norm.
Omalizumab, a novel therapy that targets specific steps in the inflammatory cascade of asthma, may benefit the hard-to-treat patient.
New oral treatment options and outcome measures may help patients with type 2 diabetes to achieve better results while reducing associated costs.
Improved outcomes with new biologic agents are prompting physicians to integrate them into therapy for psoriasis patients.
What went wrong between Penn State and Geisinger, and what lessons should be learned?
A relatively new concept in strategic management provides a way to balance quality and customer satisfaction with costs and long-range goals.
Continuous subcutaneous terbutaline infusion shows improved clinical outcomes and decreased nursery costs compared with oral tocolytics in women with recurrent preterm labor.
The appropriate application of criteria for the use of palivizumab can save health plans a significant amount of money.
The impact of this debilitating disease has been largely underestimated, yet new biologic agents offer significant clinical benefit to those afflicted.
MANAGED CARE's Weekly Poll
How will the Supreme Court rule in King v. Burwell?
Any day now, the Supreme Court will hand down its decision. How will the court rule?
In favor of Burwell, upholding the subsidies and leaving the ACA intact
68% (126 votes)
In favor of the plaintiff, King, and against premium subsidies for insurance policies sold on federally facilitated exchanges
32% (58 votes)
Total votes: 184